Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.64 |
| ▸ | TYK2 | P29597 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | MARK3 | P27448 | 2/20 | 0.49 |
| ▸ | CLK2 | P49760 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489337 | 0.87 | PDPK1 (0.64) | JAK2JAK3CHEK1KCNH2CDK2 | |
| SCHEMBL10213929 | 0.84 | JAK2 (0.81) | JAK2TYK2JAK3JAK1PLK4 | |
| SCHEMBL31690865 | 0.78 | JAK2 (1.00) | JAK2TYK2JAK3JAK1PLK4 | |
| SCHEMBL2661883 | 0.77 | GSK3B (0.54) | JAK2TYK2JAK3CHEK1KCNH2 | |
| SCHEMBL12907246 | 0.76 | JAK2 (1.00) | JAK2TYK2JAK3JAK1PLK4 | |
| SCHEMBL3359889 | 0.76 | JAK2 (1.00) | JAK2TYK2JAK3JAK1PLK4 | |
| SCHEMBL31318479 | 0.75 | KCNH2 (0.50) | CHEK1KCNH2 | |
| SCHEMBL26886503 | 0.75 | PDPK1 (0.74) | JAK2TYK2JAK3JAK1PLK4 | |
| SCHEMBL2662433 | 0.75 | JAK2 (0.56) | JAK2TYK2JAK3CHEK1JAK1 | |
| SCHEMBL12907187 | 0.75 | JAK2 (0.72) | JAK2TYK2JAK3JAK1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2157859-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | Takeda Pharmaceutical Company Limited (JP) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | GCKR, GCK, KHK | JAK2 655/4885TYK2 136/4885JAK3 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.